At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Jul 24, 2026 at 14:40 ET
Outlook Therapeutics received FDA approval for LYTENAVA (bevacizumab-vikg) for wet AMD, the first and only FDA-approved ophthalmic formulation of bevacizumab. The company anticipates 12 years of market exclusivity under the BPCIA and is launching into the ~$8.5B U.S. retina market. This is a transformative event for the company, transitioning it from a development-stage biotech to a commercial-stage entity with a first-in-class approved product.
- FDA approved LYTENAVA (bevacizumab-vikg) for neovascular (wet) age-related macular degeneration (nAMD).
- LYTENAVA is the first and only FDA-approved ophthalmic formulation of bevacizumab for wet AMD.
- Company anticipates 12 years of Reference Product Exclusivity under the BPCIA.
- U.S. anti-VEGF retina market estimated at approximately $8.5 billion annually.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access